Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Gilead Sciences Inc (GILD)

Gilead Sciences Inc (GILD)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 84,653,096
  • Shares Outstanding, K 1,274,896
  • Annual Sales, $ 22,127 M
  • Annual Income, $ 5,455 M
  • 60-Month Beta 1.12
  • Price/Sales 3.74
  • Price/Cash Flow 8.86
  • Price/Book 3.88

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 19 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/19
See More
  • Average Estimate 1.67
  • Number of Estimates 8
  • High Estimate 1.81
  • Low Estimate 1.57
  • Prior Year 1.75
  • Growth Rate Est. (year over year) -4.57%

Price Performance

See More
Period Period Low Period High Performance
1-Month
64.68 +2.66%
on 07/23/19
69.98 -5.12%
on 06/25/19
-2.98 (-4.30%)
since 06/21/19
3-Month
62.05 +7.01%
on 04/25/19
69.98 -5.12%
on 06/25/19
+3.36 (+5.33%)
since 04/23/19
52-Week
60.32 +10.08%
on 12/26/18
79.61 -16.59%
on 10/03/18
-10.98 (-14.19%)
since 07/23/18

Most Recent Stories

More News
Gilead Announces Latest Data in Ongoing HIV Cure Research Program

Gilead Sciences, Inc. (NASDAQ: GILD) today presented results from two studies of investigational toll-like receptor 7 (TLR7) agonists as part of an HIV cure research program. The Phase 1 and preclinical...

GILD : 66.40 (+2.30%)
Gilead Presents New Findings on Profile of Descovy(R) for Potential Use as HIV Pre-exposure Prophylaxis Compared With Truvada(R)

Gilead Sciences, Inc. (NASDAQ: GILD) today presented additional results from the DISCOVER trial evaluating an investigational use of Descovy (emtricitabine 200 mg and tenofovir alafenamide 25 mg tablets;...

GILD : 66.40 (+2.30%)
Is a Beat in Store for Repligen (RGEN) This Earnings Season?

On Repligen's (RGEN) second-quarter earnings call, investor focus will be on its advancement with the proposed acquisition of C Technologies, Inc.

RGEN : 87.88 (-0.45%)
GILD : 66.40 (+2.30%)
REGN : 309.26 (+4.30%)
ALXN : 122.42 (+0.08%)
AMAG (AMAG) to Report Q2 Earnings: What's in the Cards?

We expect AMAG (AMAG) to provide updates on its revenue-driving products, when it reports second-quarter earnings.

GILD : 66.40 (+2.30%)
AMAG : 8.64 (-1.82%)
REGN : 309.26 (+4.30%)
ALXN : 122.42 (+0.08%)
Human Respiratory Syncytial Virus Market Likely to Propelled Demand by Increased Incidence Rate of Chronic Respiratory Problems by 2027

According to a recently published report by Research Nester titled "delivers the detailed overview of the global human respiratory syncytial virus market in terms of market segmentation by product type,...

VRX.TO : 30.80 (-3.33%)
MRK : 82.03 (+1.01%)
GILD : 66.40 (+2.30%)
TEVA : 7.68 (-0.13%)
GSK : 41.32 (+0.46%)
Gilead Presents New Data on Biktarvy(R) for the Treatment of HIV in Women and in Virologically Suppressed Patients With Known Resistance

Gilead Sciences, Inc. (NASDAQ: GILD) today presented findings from two Phase 3 trials - a trial demonstrating the effectiveness of switching to Biktarvy (bictegravir 50mg/emtricitabine 200mg/tenofovir...

GILD : 66.40 (+2.30%)
What's in Store for Anika Therapeutics' (ANIK) Q2 Earnings?

On Anika Therapeutics' (ANIK) second-quarter earnings call, investor focus will be on its progress with the U.S. approval of its orthopedic product Cingal.

ANIK : 40.74 (-0.54%)
GILD : 66.40 (+2.30%)
REGN : 309.26 (+4.30%)
ALXN : 122.42 (+0.08%)
Gilead Presents Proof-of-Concept Data for GS-6207, a First-in-Class Capsid Inhibitor, in People Living With HIV

Gilead Sciences, Inc. (NASDAQ: GILD) today presented the first clinical data in people living with HIV on GS-6207, an investigational, novel, selective, first-in-class inhibitor of HIV capsid function....

GILD : 66.40 (+2.30%)
Q2 Earnings Surprise in the Cards, Healthcare ETFs to Buy

With earnings surprise in cards, the healthcare sector is expected to witness earnings growth of 1.7% in the second quarter, suggesting continued outperformance for healthcare ETFs.

XLV : 92.14 (+0.62%)
VHT : 172.85 (+0.44%)
MRK : 82.03 (+1.01%)
FHLC : 44.74 (+0.44%)
IYH : 194.34 (+0.59%)
ABBV : 67.73 (-0.40%)
GILD : 66.40 (+2.30%)
AMGN : 176.01 (+0.07%)
PFE : 43.09 (+0.63%)
BMY : 43.05 (+0.65%)
After Yesterday's Decline of 1.58%, Gilead Sciences Offers Investors Better Value

Gilead Sciences (NASDAQ:GILD) traded in a range yesterday that spanned from a low of $66.04 to a high of $67.34. Yesterday, the shares fell 1.6%, which took the trading range below the 3-day low of $66.46...

GILD : 66.40 (+2.30%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 16% Buy with a Weakest short term outlook on maintaining the current direction.

Longer term, the trend strength is Minimum.

See More Share

Trade GILD with:

Business Summary

Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need. The Company strive to transform and simplify care for people with life-threatening illnesses around the world. Gilead's portfolio of products...

See More

Key Turning Points

2nd Resistance Point 67.60
1st Resistance Point 67.00
Last Price 66.40
1st Support Level 65.24
2nd Support Level 64.08

See More

52-Week High 79.61
Fibonacci 61.8% 72.24
Fibonacci 50% 69.96
Fibonacci 38.2% 67.69
Last Price 66.40
52-Week Low 60.32

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar